Advances in cancer immunotherapy for gastroenterological malignancy

@inproceedings{Kono2018AdvancesIC,
  title={Advances in cancer immunotherapy for gastroenterological malignancy},
  author={Koji Kono},
  booktitle={Annals of gastroenterological surgery},
  year={2018}
}
Recent breakthrough results from immune checkpoint inhibitors (ICI) such as an anti‐cytotoxic T‐lymphocyte‐associated protein 4 (anti‐CTLA4) monoclonal antibody (mAb) (ipilimumab) and anti‐ programmed cell death‐1 (anti‐PD‐1) mAbs (nivolumab and pembrolizumab) have paved the way to a new era of cancer immunotherapy, leading to a paradigm shift in cancer treatment. Currently, ICI has had immense clinical success resulting in sustained treatment response for a subset of cancer patients such as… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS